The upcoming CHAPTER-3 topline data in 3Q2026 is the primary near-term catalyst; a positive readout could drive significant upside given the $2.4B market cap and 90% analyst bullishness. Monitor for data release and any regulatory updates ahead of the April 2027 PDUFA date.
Price Chart
Executive Summary
Pharvaris reported Q2 2026 EPS of -€0.70, a beat vs consensus of -$0.65 (9.7% beat), with no revenue. The company has €318M cash runway into 2028 and expects topline data from the pivotal CHAPTER-3 Phase 3 study of deucrictibant XR for HAE prophylaxis in 3Q2026, a key catalyst. The NDA for deucrictibant IR is under FDA review with a PDUFA date of April 23, 2027, and the EMA validated the MAA in July 2026, supporting a bullish outlook on pipeline progress.
Key Financial Metrics
Key Facts
- EPS beat consensus by 9.7% (-€0.70 actual vs -$0.65 estimate)
- Cash and cash equivalents of €318M as of June 30, 2026, extending runway into 2028
- Topline data from pivotal Phase 3 CHAPTER-3 study of deucrictibant XR expected in 3Q2026
- NDA for deucrictibant IR accepted by FDA with PDUFA date of April 23, 2027
- MAA for deucrictibant IR validated by EMA in July 2026
- Closed $132.3M underwritten offering in May 2026
Financial Impact
EPS beat of 9.7% vs consensus; cash position of €318M; $132.3M offering closed
Risk Factors
- CHAPTER-3 topline data may fail to meet efficacy or safety endpoints
- Regulatory delays or negative FDA/EMA decisions on deucrictibant IR NDA/MAA
- Dilution risk from $132.3M offering; cash burn rate may accelerate pre-launch
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3343484 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | Insider Cluster | $38.06 $36.37 | ▲ +4.44% | ▲ +5.26% | $31.07 (+18.38%) |
Sep 14, 2026 17d ago | 144 | $38.06 $35.20 | ▼ −7.51% | ▼ −9.63% | $31.07 (−18.38%) |
Sep 14, 2026 18d ago | Insider Cluster | $38.86 $36.02 | ▼ −7.31% | ▼ −7.41% | $31.07 (−20.06%) |
Sep 11, 2026 21d ago | Insider Cluster | $38.02 $36.37 | ▼ −4.34% | ▼ −4.12% | $31.07 (−18.29%) |
Sep 8, 2026 24d ago | 6-K | $37.84 $38.86 | ▲ +2.70% | ▲ +3.36% | $31.07 (−17.90%) |
Aug 12, 2026 7w ago | 6-K | $36.46 $36.27 | ▼ −0.52% | ▼ −0.08% | $31.07 (−14.80%) |
Aug 12, 2026 7w ago | Press Release | $36.46 $36.27 | ▼ −0.52% | ▼ −0.08% | $31.07 (−14.80%) |
Aug 6, 2026 8w ago | Press Release | $34.45 $34.04 | ▼ −1.19% | ▼ −2.40% | $31.07 (−9.83%) |
Jul 6, 2026 12w ago | Press Release | $33.22 $35.07 | ▲ +5.57% | ▲ +5.08% | $31.07 (−6.49%) |
Jul 1, 2026 13w ago | Insider Cluster | $33.86 $35.96 | ▲ +6.20% | ▲ +5.27% | $31.07 (−8.25%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access